Accumetrics,
Inc.
|
|
Accumetrics,
Inc. Forms Partnership with Grifols as Its Distributor in
Spain, Portugal and Chile
Accumetrics, Inc. Announces
GRAVITAS Trial 50 Percent Enrolled
Accumetrics,
Inc. Announces Distribution Channels in Israel and Cyprus
Accumetrics, Inc. Announces 1000th Patient Enrolled in
GRAVITAS Trial
Accumetrics, Inc. Announces United Kingdom Distribution
Agreement with ELITech UK Limited
Gregory J. Tibbitts Appointed Chief Financial Officer at
Accumetrics, Inc.
Cardiovascular Death and Nonfatal Myocardial Infarction in
Acute Coronary Syndrome Patients Receiving Coronary Stenting
Are Predicted by Residual Platelet Reactivity to ADP
Detected by a Point-of-Care Assay
back to top |
Alereon, Inc. |
|
Ultrawideband: Down, But Far From Out
WiMedia and UWB: where to from here?
Alereon Receives FCC Modular Certification for Worldwide
Wireless USB Half-MiniCard
Alereon Powers IOGEAR Wireless USB Solution for Home and
Office
Alereon AL5000 Family PHY Certified for WiMedia Bandgroup 6
back to top |
Apollo Endosurgery,
Inc. |
|
Most
Successful U.S. Startups 2008: Apollo Endosurgery -
BusinessWeek
Apollo Endosurgery Announces 510(k) Clearance for its
Flexible Endoscopic Suturing System
Surgery Without the Slicing
The Bleeding Edge: The drugs giants are in trouble, but medical devices are
blooming
back to top |
| Asuragen,
Inc. |
|
Mirna
Therapeutics Announces Dr. Frank Slack as Scientific Advisor
Gov. Perry Announces $5
Million Investment in Development, Commercialization of
Cancer Treatment
Tiny RNA Has Big Impact On
Lung Cancer Tumors
Chasing the
Therapeutic Potential of miRNAs
Asuragen
Signs Agreement with Biogen Idec to Pursue Companion
Diagnostic Strategy
Mirna Therapeutics presents data at
Keystone Symposium on MicroRNA and Cancer
Agilent Technologies Appoints Asuragen, Inc. as a Certified
Service Provider for its aCGH and miRNA Microarrays
Mirna Therapeutics and UCSF Researchers Initiate
Collaboration to Explore Therapeutic Potential of microRNAs
Mirna Therapeutics to Collaborate with M. D. Anderson on
miRNA Prostate Cancer Therapeutics
Asuragen Initiates Launch of CE-Marked Molecular Diagnostic
Products with the Release of the Signature® LTx v2.0
Leukemia Translocation Panel Assay in Europe
Asuragen, Inc. Launches a Multiplex qRT-PCR Assay for the
Detection of BCR/ABL1 Fusion Transcripts
back to top
|
| BioForm
Medical, Inc. (NASDAQ: BFRM) |
|
Merz to Acquire BioForm Medical
BioForm Medical Strengthens Its Board of Directors With
Three Aesthetics Industry Veterans
BioForm Medical to Launch New 1.5cc RADIESSE(r) Volume
Advantage Syringe and 0.8cc RADIESSE Moderate Fill Syringe;
Announces Successful Results of RADIESSE Dermal Filler With
Lidocaine Clinical Study
New Procedures to Drive Growth of $5 Billion Global Medical
Aesthetic Industry
One Million Syringes of RADIESSE(r) Dermal Filler Have Been
Shipped
338 Patient Pivotal Trial Demonstrates Safety and
Effectiveness of Polidocanol Sclerotherapy Product for
Varicose Vein Treatment
back to top
|
| BioMimetic
Pharmaceuticals, Inc. ("BMTI") (NASDAQ: BMTI) |
BioMimetic nears European
patent on tissue healing products
Dr. Samuel E. Lynch Presides Over the NASDAQ
Closing Bell to Celebrate
the Initial Public Offering of BioMimetic Therapeutics, Inc. [BMTI]
back
to top |
| BioSurface
Engineering
Technologies,
Inc. ("BioSET") |
|
Brookhaven Lab and BioSET, Inc., Patent a Synthetic Peptide
That Enhances Bone Growth
BioSET Announces Initiation Of Clinical Trials For AMPLEX
Osteo-Promotive Bone Graft System For Spine Fusion
Tornier and Bioset Enter Synthetic Growth Factor Pact
Synthetic Peptide That Enhances the Effect of a Bone Growth Factor,
BMP-2
back
to top
|
| Cameron Health, Inc. |
|
The rhythm of life
Cameron Health Commences Clinical Trial of the Minimally
Invasive Totally Subcutaneous Implantable Defibrillator for
Treatment of Sudden Cardiac Arrest
Internal External Defibrillator: A new device may offer a
safer way to jump-start ailing hearts
back
to top |
| Cardiva Medical, Inc. |
|
Cardiva Medical, Inc. Receives FDA Clearance for the
Catalyst III System
Cardiva Medical, Inc. Announces Presentation at the 2008 UBS
Global Life Science Conference
Cardiva Medical, Inc. Announces Presentation at the BMO
Capital Markets 2008 Focus on Healthcare Conference
Global Vascular Closure Device Market to Exceed $900 Million by 2013
Cardiva Medical, Inc. to Present at the 'Investment In Innovation (In3)
Medical Device Summit' on June 18, 2008 in San
Francisco, CA; Announces the
Completion of Its Latest Phase in Its US Sales Force Expansion
back
to top |
| GlycoMimetics,
Inc. ("GMI") |
|
GlycoMimetics, Inc. Attracts $38
Million in Latest Venture Round
New Drug to
Treat Sickle Cell Crisis Begins Pilot Study in Patients
GlycoMimetics, Inc. Awarded NIH Grant to Study Drug
Candidate in Diabetes
GlycoMimetics, Inc. Completes Phase 1 Clinical Studies
of Lead Drug Candidate
GlycoMimetics, Inc. Selected to Present Preclinical Data on
Lead Drug Candidate at 50th Annual Meeting of the American
Society of Hematology
GlycoMimetics, Inc. Commences Phase 1 Clinical Trial of Lead
Drug Candidate
GlycoMimetics, Inc. to Present Results of Lead Candidate in Animal
Models of Sickle Cell Disease at American Society of Hematology Annual
Meeting
back to top |
| IDEV
Technologies, Inc. |
|
MEDICAL TECHNOLOGY, A vessel to grow
- Houston Chronicle
U.S. Food and Drug Administration Clears Way for Multicenter
Clinical Trial of IDEV Technologies’ SUPERA Peripheral Stent
IDev(R) Technologies Inc. Announces Distribution Partnership with YMed Inc.
for the VascuTrak 2(TM) Focal Force PTA Catheter
Wire-Interwoven Nitinol: A new class of stents may expand treatment options
for patients with peripheral arterial disease
back to top |
| InSite
Vision, Inc. ("ISV") (INSV.OB) |
|
InSite Vision Signs International Licensing and Distribution
Agreement for AzaSite((R)) in Japan and Taiwan With Nitten
Pharmaceutical Co., Ltd
InSite Vision Receives Regulatory Approval for AzaSite® in
Canada
InSite Vision Announces Restructuring to Support 2009
Strategic Priorities
InSite Vision Announces FDA Advisory Committee's Unanimous
Recommendation of Approval for New Ophthalmic Product
Enabled by InSite's DuraSite(R) Technology
InSite Vision Announces Preliminary Results From Phase 3
Clinical Trial of ISV-502 for the Treatment of Eyelid
Inflammation and Infection
back to top |
|
Intersect ENT, Inc. (formerly Sinexus) |
Sinexus Changes Name to Intersect ENT, Initiates Pivotal
Study
back
to top
|
| LDR
Spine USA, Inc. ("LDR") |
|
1st Mobi-C® cervical artificial disc implanted in China
LDR Announces FDA Clearance of its ROI-A™ ALIF Device
LDR opens direct sales channel in Germany
LDR obtains approval in China for their Mobi-C® cervical
artificial disc
LDR strengthens international position expanding Latin
American presence
back
to top |
| On-X® Life Technologies, Inc. |
|
On-X Life Technologies Doubles Manufacturing Space in Austin
Examination of
hemolytic potential with the On-X(R) prosthetic heart valve
Austin-Based Medical Carbon Research Institute, LLC. Becomes On-X Life
Technologies, Inc.
back
to top |
| Ortho
Kinematics, Inc. |
Gov. Perry: We Must Invest Wisely to Help Texans and
Strengthen Our Economy
back
to top |
| OsteoBiologics,
Inc. ("OBI")
- Acquired by: Smith & Nephew |
Smith &
Nephew Acquires OBI, Inc.
back
to top |
| Tryton Medical, Inc. |
|
TRYTON Announces Registry
Evaluating Tryton Stent System for Left Main Disease and
Celebrates 500th Implant
Tryton
Celebrates 250th Implant of Innovative Side Branch Stent
System
Tryton
Announces First Patient Enrollment in E-Tryton 150 Registry
Tryton Medical introduces Side Branch Stent System in Europe
Tryton Medical Announces Two Key Hires and Relocation to
Research Triangle Park, N.C
Tryton Medical Appoints VP Sales & Marketing EU
Tryton Medical Appoints President and CEO
Tryton Medical, Inc. Closes $14 Million Financing
back
to top |
| ZIOPHARM Oncology, Inc. (NASDAQ:
ZIOP) |
|
ZIOPHARM Presents Positive
Darinaparsin Clinical Data at ASCO's Prestigious Clinical
Science Symposium
ZIOPHARM Presents Positive
Data from Phase I Study of Palifosfamide in Combination with
Doxorubicin at ASCO
ZIOPHARM
Presents Positive Indibulin Translationaland Dose Scheduling
Data at ASCO
ZIOPHARM Presentations at the American Society of Clinical
Oncology (ASCO) Annual Meeting
Market for Multiple Myeloma Therapeutics in the US to Reach
$4.0 Billion by 2015
back
to top |
| |
| |
| |
|
